VisiCELL Medical

Executive Summary

VisiCELL Medical is pioneering a novel imaging analytics platform that acts as a 'GPS for Cell Therapy,' enabling real-time, non-invasive tracking of therapeutic cells in vivo using MRI. Founded in 2015 and based in San Diego, the company addresses a critical unmet need in cell therapy development: the inability to monitor cell biodistribution, persistence, and function after administration. By providing actionable insights through advanced MRI-based imaging analytics, VisiCELL aims to accelerate clinical translation, reduce development timelines, and improve therapeutic outcomes across oncology, autoimmune disease, and regenerative medicine. Its technology has the potential to de-risk cell therapy programs and optimize dosing regimens, ultimately driving better economic and patient outcomes. Currently in pre-clinical stages, VisiCELL is positioning itself as a key enabler for the cell therapy industry, where tracking and verifying cell behavior remains a major challenge. The platform could become an essential tool for developers seeking regulatory approval and commercial success.

Upcoming Catalysts (preview)

• Q2 2026Partnership with a leading cell therapy developer for platform validation60% success
• Q4 2026IND filing for lead imaging indication40% success
• Q3 2026Presentation of preclinical proof-of-concept data at a major cell therapy conference70% success